Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis
Fei Lu,1,2 Yu Hou,1 Yaoxiong Xia,1 Lan Li,1 Li Wang,1 Ke Cao,1 Haixia Chen,1 Li Chang,1 Wenhui Li11Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan, People’s Republic of China; 2Department of O...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-05-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/survival-and-intracranial-control-outcomes-of-whole-brain-radiotherapy-peer-reviewed-article-CMAR |
| _version_ | 1819010720718651392 |
|---|---|
| author | Lu F Hou Y Xia YX Li L Wang L Cao K Chen HX Chang L Li WH |
| author_facet | Lu F Hou Y Xia YX Li L Wang L Cao K Chen HX Chang L Li WH |
| author_sort | Lu F |
| collection | DOAJ |
| description | Fei Lu,1,2 Yu Hou,1 Yaoxiong Xia,1 Lan Li,1 Li Wang,1 Ke Cao,1 Haixia Chen,1 Li Chang,1 Wenhui Li11Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan, People’s Republic of China; 2Department of Oncology and Hematology, The First People’s Hospital of Honghe State, Mengzi, Yunnan, People’s Republic of ChinaPurpose: To compare the differences in survival and intracranial local control between patients treated with whole-brain radiotherapy (WBRT) and WBRT plus a radiotherapy boost (RTB) in non-small-cell lung cancer (NSCLC) patients with brain metastases (BMs).Patients and methods: Between May 2010 and October 2017, 206 NSCLC patients with BMs were treated with brain radiotherapy; among these patients, 140 patients underwent WBRT alone (group A) and 66 patients underwent WBRT plus RTB (group B). The endpoints included intracranial local progression-free survival and regional progression-free survival time (iLPFS and iRPFS, respectively) and overall survival (OS).Results: Between the two groups, not all baseline clinical factors were well-balanced. The median iLPFS was 17.9 months in group A and 22.3 months in group B. The 2-year iLPFS rates were significantly lower in group A than in group B (34.5% vs 49.3%, P=0.041); however, no significant differences were observed in OS or iRPFS. Multivariate analyses revealed that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) therapy was significantly associated with good OS, iLPFS, and iRPFS. Among the patients treated with TKIs (n=62), there were no differences in OS (P=0.190), iLPFS (P=0.334), or iRPFS (P=0.338) between groups A and B. In the patients without TKI treatment (n=102), the median iLPFS was significantly longer in group B than in group A (16.7 vs 12.0 months, P=0.032), but no significant differences were found in OS (p=0.182) or iRPFS (P=0.837) between the two groups.Conclusion: WBRT plus RTB significantly improved iLPFS compared with WBRT alone, especially in patients without EGFR-TKI treatment. However,there were no significant differences in iRPFS or OS between the two groups. Patients treated with EGFR-TKIs may not benefit from WBRT plus RTB.Keywords: non-small-cell lung carcinoma, brain metastases, brain radiotherapy, radiotherapy boost, tyrosine kinase inhibitor |
| first_indexed | 2024-12-21T01:16:45Z |
| format | Article |
| id | doaj.art-b4420fa0e5e54f83a1b1852028f85ea4 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-21T01:16:45Z |
| publishDate | 2019-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-b4420fa0e5e54f83a1b1852028f85ea42022-12-21T19:20:46ZengDove Medical PressCancer Management and Research1179-13222019-05-01Volume 114255427245705Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysisLu FHou YXia YXLi LWang LCao KChen HXChang LLi WHFei Lu,1,2 Yu Hou,1 Yaoxiong Xia,1 Lan Li,1 Li Wang,1 Ke Cao,1 Haixia Chen,1 Li Chang,1 Wenhui Li11Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan, People’s Republic of China; 2Department of Oncology and Hematology, The First People’s Hospital of Honghe State, Mengzi, Yunnan, People’s Republic of ChinaPurpose: To compare the differences in survival and intracranial local control between patients treated with whole-brain radiotherapy (WBRT) and WBRT plus a radiotherapy boost (RTB) in non-small-cell lung cancer (NSCLC) patients with brain metastases (BMs).Patients and methods: Between May 2010 and October 2017, 206 NSCLC patients with BMs were treated with brain radiotherapy; among these patients, 140 patients underwent WBRT alone (group A) and 66 patients underwent WBRT plus RTB (group B). The endpoints included intracranial local progression-free survival and regional progression-free survival time (iLPFS and iRPFS, respectively) and overall survival (OS).Results: Between the two groups, not all baseline clinical factors were well-balanced. The median iLPFS was 17.9 months in group A and 22.3 months in group B. The 2-year iLPFS rates were significantly lower in group A than in group B (34.5% vs 49.3%, P=0.041); however, no significant differences were observed in OS or iRPFS. Multivariate analyses revealed that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) therapy was significantly associated with good OS, iLPFS, and iRPFS. Among the patients treated with TKIs (n=62), there were no differences in OS (P=0.190), iLPFS (P=0.334), or iRPFS (P=0.338) between groups A and B. In the patients without TKI treatment (n=102), the median iLPFS was significantly longer in group B than in group A (16.7 vs 12.0 months, P=0.032), but no significant differences were found in OS (p=0.182) or iRPFS (P=0.837) between the two groups.Conclusion: WBRT plus RTB significantly improved iLPFS compared with WBRT alone, especially in patients without EGFR-TKI treatment. However,there were no significant differences in iRPFS or OS between the two groups. Patients treated with EGFR-TKIs may not benefit from WBRT plus RTB.Keywords: non-small-cell lung carcinoma, brain metastases, brain radiotherapy, radiotherapy boost, tyrosine kinase inhibitorhttps://www.dovepress.com/survival-and-intracranial-control-outcomes-of-whole-brain-radiotherapy-peer-reviewed-article-CMARnon-small cell lung carcinomabrain metastasesbrain radiotherapyradiotherapy boosttyrosine kinase inhibitor. |
| spellingShingle | Lu F Hou Y Xia YX Li L Wang L Cao K Chen HX Chang L Li WH Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis Cancer Management and Research non-small cell lung carcinoma brain metastases brain radiotherapy radiotherapy boost tyrosine kinase inhibitor. |
| title | Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis |
| title_full | Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis |
| title_fullStr | Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis |
| title_full_unstemmed | Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis |
| title_short | Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis |
| title_sort | survival and intracranial control outcomes of whole brain radiotherapy wbrt alone versus wbrt plus a radiotherapy boost in non small cell lung cancer with brain metastases a single institution retrospective analysis |
| topic | non-small cell lung carcinoma brain metastases brain radiotherapy radiotherapy boost tyrosine kinase inhibitor. |
| url | https://www.dovepress.com/survival-and-intracranial-control-outcomes-of-whole-brain-radiotherapy-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT luf survivalandintracranialcontroloutcomesofwholebrainradiotherapywbrtaloneversuswbrtplusaradiotherapyboostinnonsmallcelllungcancerwithbrainmetastasesasingleinstitutionretrospectiveanalysis AT houy survivalandintracranialcontroloutcomesofwholebrainradiotherapywbrtaloneversuswbrtplusaradiotherapyboostinnonsmallcelllungcancerwithbrainmetastasesasingleinstitutionretrospectiveanalysis AT xiayx survivalandintracranialcontroloutcomesofwholebrainradiotherapywbrtaloneversuswbrtplusaradiotherapyboostinnonsmallcelllungcancerwithbrainmetastasesasingleinstitutionretrospectiveanalysis AT lil survivalandintracranialcontroloutcomesofwholebrainradiotherapywbrtaloneversuswbrtplusaradiotherapyboostinnonsmallcelllungcancerwithbrainmetastasesasingleinstitutionretrospectiveanalysis AT wangl survivalandintracranialcontroloutcomesofwholebrainradiotherapywbrtaloneversuswbrtplusaradiotherapyboostinnonsmallcelllungcancerwithbrainmetastasesasingleinstitutionretrospectiveanalysis AT caok survivalandintracranialcontroloutcomesofwholebrainradiotherapywbrtaloneversuswbrtplusaradiotherapyboostinnonsmallcelllungcancerwithbrainmetastasesasingleinstitutionretrospectiveanalysis AT chenhx survivalandintracranialcontroloutcomesofwholebrainradiotherapywbrtaloneversuswbrtplusaradiotherapyboostinnonsmallcelllungcancerwithbrainmetastasesasingleinstitutionretrospectiveanalysis AT changl survivalandintracranialcontroloutcomesofwholebrainradiotherapywbrtaloneversuswbrtplusaradiotherapyboostinnonsmallcelllungcancerwithbrainmetastasesasingleinstitutionretrospectiveanalysis AT liwh survivalandintracranialcontroloutcomesofwholebrainradiotherapywbrtaloneversuswbrtplusaradiotherapyboostinnonsmallcelllungcancerwithbrainmetastasesasingleinstitutionretrospectiveanalysis |